Ultragenyx Submits Gene Therapy for Sanfilippo Syndrome to EMA
Event summary
- Ultragenyx submitted a Marketing Authorisation Application (MAA) to the EMA for rebisufligene etisparvovec, a gene therapy for MPS IIIA (Sanfilippo Syndrome Type A).
- EMA validation confirms the application is complete for review, but does not guarantee approval.
- Rebisufligene etisparvovec received FDA approval on September 17th, 2026.
- The therapy has PRIME and Orphan Drug Designations from the EMA.
- Ultragenyx is pursuing regulatory engagement with the MHRA and SFDA for potential geographic expansion.
The big picture
Ultragenyx's submission to the EMA for rebisufligene etisparvovec marks a critical step in addressing the unmet medical need for Sanfilippo Syndrome Type A, a rare and fatal lysosomal storage disease. The validation of the MAA by the EMA underscores the urgency and significance of developing therapies for ultra-rare genetic diseases. The company's strategic focus on expanding regulatory approvals globally positions it to potentially capture a niche market with high barriers to entry.
What we're watching
- Regulatory Timeline
- The pace at which the EMA completes its review and whether it requests additional data.
- Geographic Expansion
- Ultragenyx's ability to secure approvals in the UK and Saudi Arabia following the EMA review.
- Market Access
- How the Joint Clinical Assessment (JCA) framework impacts patient access across EU Member States.